Literature DB >> 32941916

Health-Related QOL and Economic Burden of Chronic Pruritus.

Katherine A Whang1, Raveena Khanna1, Kyle A Williams1, Varun Mahadevan1, Yevgeniy Semenov2, Shawn G Kwatra3.   

Abstract

Chronic pruritus (CP) has considerable implications for QOL. However, its impact on health-related QOL and economic burden is not fully characterized. We administered a cross-sectional survey on 132 patients with CP using the Health Utilities Index Mark 3 instrument. Normative data from healthy adults (n = 4,187) were obtained from the Joint Canada/US Survey of Health. Quality-adjusted life-year loss and economic costs were estimated on the basis of Health Utilities Index Mark 3 scores of patients with CP versus controls. Patients with CP had lower overall health performance than the control (0.56 ± 0.03 vs. 0.86 ± 0.003, P < 0.001). In multivariable regression, CP was associated with worse overall health performance (coefficient = -0.30, 95% confidence interval = -0.33 to -0.27), most accentuated in the domains of pain (coefficient = -0.24, confidence interval = -0.28 to -0.21) and emotion (coefficient = -0.11, confidence interval = -0.13 to -0.10). The reduced Health Utilities Index Mark 3 score correlated with 5.5 average lifetime quality-adjusted life-years lost per patient. Using conservative estimates for willingness to pay, the quality-adjusted life-year loss translated to an individual lifetime economic burden of $274,921 and a societal burden of $88.8 billion. CP is associated with significant QOL impairment. The economic burden of CP highlights the necessity for further research into management options.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32941916     DOI: 10.1016/j.jid.2020.08.020

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  10 in total

Review 1.  IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses.

Authors:  Youkyung S Roh; Justin Choi; Nishadh Sutaria; Micah Belzberg; Madan M Kwatra; Shawn G Kwatra
Journal:  Drugs       Date:  2021-04-21       Impact factor: 9.546

2.  Reduced serum pyridoxine and 25-hydroxyvitamin D levels in adults with chronic pruritic dermatoses.

Authors:  Martin Alphonse; Shawn G Kwatra; Shilpa Gopinath; Nishadh Sutaria; Zachary A Bordeaux; Varsha Parthasarathy; Junwen Deng; Matthew T Taylor; Melika Marani; Kevin Lee; Thomas Pritchard; Ali Alajmi; Waleed Adawi; Olusola O Oladipo; Yevgeniy R Semenov
Journal:  Arch Dermatol Res       Date:  2022-05-10       Impact factor: 3.017

Review 3.  Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics.

Authors:  Shawn G Kwatra; Laurent Misery; Claire Clibborn; Martin Steinhoff
Journal:  Clin Transl Immunology       Date:  2022-05-09

Review 4.  Itch: Epidemiology, clinical presentation, and diagnostic workup.

Authors:  Youkyung S Roh; Justin Choi; Nishadh Sutaria; Shawn G Kwatra
Journal:  J Am Acad Dermatol       Date:  2021-08-21       Impact factor: 11.527

5.  A Nationwide Study of Prurigo Nodularis: Disease Burden and Healthcare Utilization in the United States.

Authors:  Shannon Wongvibulsin; Nishadh Sutaria; Kyle A Williams; Amy H Huang; Justin Choi; Youkyung Sophie Roh; Michael Hong; Davis Kelley; Vartan Pahalyants; William Murphy; Martin Prince Alphonse; Pegah Bakhshi; Anant Walia; Yevgeniy R Semenov; Shawn G Kwatra
Journal:  J Invest Dermatol       Date:  2021-04-03       Impact factor: 7.590

Review 6.  Acupuncture for the Treatment of Itch: Peripheral and Central Mechanisms.

Authors:  Yi Tang; Shirui Cheng; Jin Wang; Yin Jin; Haodong Yang; Qihui Lin; Sanmei Xu; Lin Hui; Quanying Yin; Ying Yang; Xi Wu
Journal:  Front Neurosci       Date:  2022-03-30       Impact factor: 4.677

Review 7.  Interleukin-31 as a Clinical Target for Pruritus Treatment.

Authors:  Kenji Kabashima; Hiroyuki Irie
Journal:  Front Med (Lausanne)       Date:  2021-02-12

Review 8.  Interleukin-31 and Pruritic Skin.

Authors:  Masutaka Furue; Mihoko Furue
Journal:  J Clin Med       Date:  2021-04-28       Impact factor: 4.241

9.  Epidemiology, Comorbidities, and Prescription Patterns of Korean Prurigo Nodularis Patients: A Multi-Institution Study.

Authors:  Yu-Ri Woo; Sehee Wang; Kyung-Ah Sohn; Hei-Sung Kim
Journal:  J Clin Med       Date:  2021-12-24       Impact factor: 4.241

10.  Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications.

Authors:  Sarina Elmariah; Sarah Chisolm; Thomas Sciascia; Shawn G Kwatra
Journal:  JAAD Int       Date:  2022-04-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.